NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Intellia Therapeutics's NTLA short percent of float has risen 11.06% since its last report. The company recently reported ...

NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Pomerantz LLP is investigating claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Intellia Therapeutics has said it will reduce its headcount by 27% this year and shelve early-stage R&D programmes as it puts its resources behind two priority drug candidates. The specialist in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

As wildfire survivors struggle to begin the long rebuilding process, many are being deluged with solicitations from lawyers using unethical and unscrupulous tactics. In an article published by the ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...